PMV Pharmaceuticals (NASDAQ:PMVP – Get Free Report) posted its quarterly earnings results on Friday. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.03, Zacks reports.
PMV Pharmaceuticals Price Performance
NASDAQ:PMVP opened at $0.88 on Friday. The company has a fifty day moving average price of $1.07 and a 200 day moving average price of $1.36. The stock has a market cap of $45.86 million, a P/E ratio of -0.88 and a beta of 1.50. PMV Pharmaceuticals has a one year low of $0.82 and a one year high of $2.26.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of PMV Pharmaceuticals in a research note on Thursday, March 20th.
About PMV Pharmaceuticals
PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.
Featured Stories
- Five stocks we like better than PMV Pharmaceuticals
- Why Invest in 5G? How to Invest in 5G Stocks
- Constellation Powers Up With Reinforced AI Data Center Strategy
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Top Analyst-Rated Healthcare Stocks to Watch Now
- The 3 Best Blue-Chip Stocks to Buy Now
- GlobalFoundries Stock Hits Bottom: Is a Rebound Coming?
Receive News & Ratings for PMV Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PMV Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
